Neoantigen Targeted Therapies Market by Therapy Modality (Adoptive Cell Therapy, Personalized Neoantigen Vaccines), Treatment Approach (Combination Therapy, Monotherapy), Route of Administration, Age Group, Target Disease Indication, End-User - Global For
Description
The Neoantigen Targeted Therapies Market was valued at USD 4.57 billion in 2024 and is projected to grow to USD 5.30 billion in 2025, with a CAGR of 16.57%, reaching USD 15.61 billion by 2032.
Setting the Stage for Neoantigen Targeted Therapies to Revolutionize Cancer Care by Harnessing Individualized Immune Responses and Precision Oncology Approaches
The emergence of neoantigen targeted therapies marks a pivotal shift in oncology by harnessing the patient’s own tumor-specific mutations to elicit precise immune responses. Neoantigens, derived from unique genetic alterations in malignant cells, present highly individualized targets that conventional treatments often overlook. As a result, the scientific community has embraced a new paradigm in which personalized immunotherapies can address tumor heterogeneity and minimize off-target effects.
Technological breakthroughs in next-generation sequencing and advanced bioinformatics have accelerated the identification and validation of actionable neoantigens. By integrating high-throughput genomic profiling with sophisticated predictive algorithms, researchers can now pinpoint candidate targets with unprecedented accuracy. Moreover, innovations in synthetic biology and vaccine delivery platforms have facilitated the rapid translation of these discoveries into clinical-grade products.
Consequently, several clinical trials have reported promising outcomes in terms of durable responses and improved safety profiles. These developments not only underscore the therapeutic potential of neoantigen strategies but also demonstrate how collaborative efforts between academic institutions, biotech pioneers, and regulatory agencies can expedite the path from discovery to patient care. As a result, neoantigen targeted therapies stand on the cusp of redefining precision oncology and reshaping treatment guidelines across multiple cancer types.
Unveiling the Paradigm Shifts Propelling Neoantigen Targeted Therapies from Early Research to Mainstream Therapeutic Modalities through Cutting Edge Innovations
Transformative shifts within the neoantigen landscape have been driven by converging advances in computational biology, cell manufacturing, and regulatory alignment. Artificial intelligence and machine learning frameworks now enable the rapid prediction of immunogenic peptide sequences, significantly reducing the cycle time from tumor biopsy to therapeutic formulation. Concurrently, modular manufacturing platforms have scaled to accommodate personalized production, ensuring consistent quality while maintaining GMP compliance.
Regulatory bodies have responded to these advancements by offering adaptive trial designs and expedited approval pathways, thereby lowering barriers to clinical adoption. Industry partnerships have further propelled innovation, as established pharmaceutical firms collaborate with emerging biotech innovators to integrate neoantigen approaches into broader immuno-oncology portfolios. The result is a robust ecosystem that fosters iterative improvements in efficacy, safety, and patient accessibility.
These paradigm shifts have prompted realignment of R&D priorities, with stakeholders increasingly focusing on combinatorial regimens that pair neoantigen therapies with checkpoint inhibitors or adoptive cell transfers. This integrative strategy aims to amplify antitumor immunity while mitigating mechanisms of immune evasion. In sum, the confluence of technological prowess, regulatory support, and strategic collaboration is redefining the trajectory of neoantigen targeted therapies.
Analyzing the Compound Effects of United States Tariffs in 2025 on Global Supply Chains and Access to Critical Components for Neoantigen Therapy Development
The introduction of new United States tariffs in 2025 has exerted a compounded effect on the global supply chains that underpin neoantigen therapy development. Many critical reagents, such as proprietary sequencing kits, custom oligonucleotides, and specialized cell culture media, originate from tariff-impacted jurisdictions. Consequently, manufacturers have encountered elevated procurement costs, which in turn influence overall production economics and downstream pricing models.
In response, several stakeholders have diversified sourcing strategies by establishing alternative supply nodes in lower-tariff regions or by vertically integrating key manufacturing steps. This reconfiguration of the supply chain has mitigated some cost pressures but has also necessitated additional capital investment in facility upgrades and quality control processes. At the same time, collaborative agreements between suppliers and developers have been renegotiated to share risk and reduce lead times for component delivery.
Moreover, the tariff environment has accelerated innovation in reagent design, prompting suppliers to develop in-house alternatives and generic substitutes that circumvent tariff-sensitive inputs. While these adaptations involve rigorous validation to ensure equivalence, they ultimately contribute to greater supply chain resilience. As a result, the industry is better positioned to maintain consistent production schedules and uphold stringent quality standards despite evolving trade policies.
Dissecting Multifaceted Segmentation Dynamics to Illuminate How Therapy Modalities Demographics Administration Routes and End Users Shape the Neoantigen Market
The neoantigen therapy market encompasses a sophisticated array of modalities, beginning with adoptive cell therapies such as CAR-T, TCR, and tumor-infiltrating lymphocytes that are engineered to recognize and eradicate tumor cells bearing unique mutation-derived antigens. Alongside these cell-based approaches, personalized neoantigen vaccines-ranging from dendritic cell constructs to nucleic acid vaccines and synthetic long peptides-leverage distinct mechanisms to prime the immune system against malignancy.
Treatment paradigms diverge further into monotherapy protocols, which isolate neoantigen strategies as standalone agents, and combination regimens that integrate checkpoint inhibitors or targeted biologics to potentiate immune activation. The selection of administration routes, whether oral formulations or parenteral delivery via intramuscular, intravenous, or subcutaneous injections, influences pharmacokinetic profiles and patient convenience. Age demographics, spanning adult, geriatric, and pediatric populations, necessitate tailored safety assessments and dosing strategies to address developmental and physiological differences.
Target disease indications, from bone and colorectal cancers to gynecological, non-small cell lung, and renal carcinomas, reflect the broad applicability of neoantigen therapeutics. End users including academic and government research institutes, hospitals and clinics, and specialty treatment centers shape adoption patterns based on infrastructure maturity and reimbursement frameworks. Each segmentation layer contributes unique insights into development priorities and market dynamics, guiding stakeholders toward optimized clinical strategies and resource allocation.
Mapping Regional Divergence in Neoantigen Targeted Therapeutics Adoption by Examining Market Drivers and Challenges across the Americas EMEA and Asia-Pacific Territories
Regional landscapes exhibit pronounced divergence in the uptake and maturation of neoantigen targeted therapies. In the Americas, robust investment ecosystems and well-established clinical trial networks drive rapid initiation of first-in-human studies and facilitate early adoption of personalized immunotherapies. Regulatory agencies in this region have demonstrated a willingness to grant breakthrough designations and provide scientific guidance that accelerates development timelines.
Across Europe, the Middle East, and Africa, varied regulatory frameworks and reimbursement mechanisms create both opportunities and challenges. Several countries have established innovation corridors to pilot advanced therapies under controlled access programs, while others navigate complex pricing negotiations and limited manufacturing capacity. Collaborative consortia are emerging to harmonize standards and share best practices for neoantigen identification and clinical validation.
In the Asia-Pacific region, expansive population bases and government-led biotechnology initiatives have spurred significant growth in research infrastructure. Nations within this territory are investing in regional manufacturing hubs and forging public-private partnerships to expedite local production of neoantigen kits and cell therapy platforms. Collectively, these strategic efforts are fostering a dynamic environment that supports both clinical innovation and commercial scalability.
Profiling Leading Innovators and Strategic Collaborators Driving the Evolution of Neoantigen Therapies with Their Unique Technological Advancements and Commercial Alliances
Leading innovators have emerged at the intersection of genomics, immunology, and biomanufacturing, advancing proprietary platforms for neoantigen discovery and validation. Several biotech enterprises have established integrated pipelines that span in silico epitope prediction, synthetic vaccine formulation, and GMP-compliant production of personalized therapies. Strategic alliances between cell therapy specialists and major pharmaceutical firms have further enhanced distribution capabilities and global reach.
Partnerships with academic research centers underpin collaborative efforts to refine antigen selection algorithms and to explore novel vaccine adjuvants. These alliances facilitate access to patient cohorts for biomarker discovery and early-phase trials. Additionally, contract development and manufacturing organizations have expanded their service offerings to support personalized immunotherapies, delivering end-to-end solutions from vector design to cryopreserved cell delivery.
Competitive differentiation is increasingly tied to the strength of intellectual property portfolios, the breadth of clinical pipelines, and successful demonstration of durable responses in late-stage trials. Companies that can seamlessly integrate cutting-edge bioinformatics, rapid manufacturing workflows, and strategic payer engagement are poised to capture leadership positions in this rapidly evolving sector.
Generating Strategic Imperatives and Operational Directives to Enable Industry Leaders to Capitalize on Neoantigen Therapy Innovations and Navigate Complex Regulatory Landscapes
Industry leaders should prioritize investment in scalable manufacturing platforms that can accommodate personalized production without compromising quality or regulatory compliance. Establishing flexible facilities equipped for both cell therapy expansion and vaccine assembly will enable rapid adaptation to emerging modalities. Concurrently, integrating advanced bioinformatics and machine learning tools will refine neoantigen prediction accuracy and reduce development cycles.
Engagement with regulatory authorities through early scientific advice and adaptive trial designs will de-risk clinical pathways and foster mutual understanding of novel endpoints. Forming cross-sector partnerships, including alliances with contract development and manufacturing organizations, will optimize resource utilization and expand geographic reach. Moreover, forging collaborations with payers and health technology assessment bodies can streamline reimbursement strategies and support value-based pricing models.
Finally, cultivating a robust ecosystem for data sharing-encompassing clinical outcomes, biomarker insights, and manufacturing performance-will accelerate collective learning and drive continuous improvement. By embracing these strategic imperatives, industry leaders can strengthen their competitive advantage and ensure sustainable growth in the neoantigen therapy arena.
Detailing the Comprehensive Research Framework Underpinning the Analysis Including Data Collection Techniques Expert Inputs and Analytical Models to Ensure Rigor
This research employs a holistic methodology combining primary and secondary data sources to ensure accuracy and comprehensiveness. Primary research involved in-depth interviews with key opinion leaders, industry executives, manufacturing specialists, and regulatory consultants to capture nuanced perspectives on technological trends and market dynamics. Secondary research encompassed an exhaustive review of peer-reviewed publications, clinical trial registries, patent filings, and regulatory filings to corroborate insights.
Data triangulation techniques were applied to validate findings across multiple sources and to identify areas of convergence and divergence. Quantitative data was supplemented with qualitative assessments to contextualize emerging themes. Analytical models, including trend analyses and scenario planning frameworks, were utilized to interpret the impact of external factors such as trade policies and demographic shifts.
A peer review process with external subject matter experts was conducted to ensure methodological rigor and to mitigate potential biases. All research activities adhered to ethical guidelines governing data privacy and intellectual property. The resulting insights reflect a balanced, evidence-based perspective on the evolving landscape of neoantigen targeted therapies.
Summarizing Pivotal Insights from the Neoantigen Therapeutics Landscape to Reinforce Strategic Priorities and Encourage Informed Decision Making in Precision Oncology
Neoantigen targeted therapies represent a transformative frontier in precision oncology, offering the promise of highly specific, patient-tailored immune interventions. Technological advances in genomic profiling, bioinformatics, and manufacturing have catalyzed rapid progress from discovery to clinical application. At the same time, evolving regulatory frameworks and strategic partnerships have created a fertile environment for innovation and commercialization.
However, challenges remain in the areas of supply chain resilience, reimbursement pathways, and scalable manufacturing. Tariff fluctuations, regional disparities in regulatory and infrastructure capacity, and the complexity of personalized production underscore the need for adaptive strategies. By understanding segmentation nuances across therapy modalities, demographic cohorts, administration routes, and therapeutic indications, stakeholders can better align research priorities with market opportunities.
Moving forward, sustained collaboration among industry, academia, regulators, and payers will be essential to fully realize the clinical and commercial potential of neoantigen therapies. As the field continues to mature, organizations that invest in cutting-edge technologies, strategic alliances, and data-driven decision making will be best positioned to lead the charge in this next era of cancer treatment.
Please Note: PDF & Excel + Online Access - 1 Year
Setting the Stage for Neoantigen Targeted Therapies to Revolutionize Cancer Care by Harnessing Individualized Immune Responses and Precision Oncology Approaches
The emergence of neoantigen targeted therapies marks a pivotal shift in oncology by harnessing the patient’s own tumor-specific mutations to elicit precise immune responses. Neoantigens, derived from unique genetic alterations in malignant cells, present highly individualized targets that conventional treatments often overlook. As a result, the scientific community has embraced a new paradigm in which personalized immunotherapies can address tumor heterogeneity and minimize off-target effects.
Technological breakthroughs in next-generation sequencing and advanced bioinformatics have accelerated the identification and validation of actionable neoantigens. By integrating high-throughput genomic profiling with sophisticated predictive algorithms, researchers can now pinpoint candidate targets with unprecedented accuracy. Moreover, innovations in synthetic biology and vaccine delivery platforms have facilitated the rapid translation of these discoveries into clinical-grade products.
Consequently, several clinical trials have reported promising outcomes in terms of durable responses and improved safety profiles. These developments not only underscore the therapeutic potential of neoantigen strategies but also demonstrate how collaborative efforts between academic institutions, biotech pioneers, and regulatory agencies can expedite the path from discovery to patient care. As a result, neoantigen targeted therapies stand on the cusp of redefining precision oncology and reshaping treatment guidelines across multiple cancer types.
Unveiling the Paradigm Shifts Propelling Neoantigen Targeted Therapies from Early Research to Mainstream Therapeutic Modalities through Cutting Edge Innovations
Transformative shifts within the neoantigen landscape have been driven by converging advances in computational biology, cell manufacturing, and regulatory alignment. Artificial intelligence and machine learning frameworks now enable the rapid prediction of immunogenic peptide sequences, significantly reducing the cycle time from tumor biopsy to therapeutic formulation. Concurrently, modular manufacturing platforms have scaled to accommodate personalized production, ensuring consistent quality while maintaining GMP compliance.
Regulatory bodies have responded to these advancements by offering adaptive trial designs and expedited approval pathways, thereby lowering barriers to clinical adoption. Industry partnerships have further propelled innovation, as established pharmaceutical firms collaborate with emerging biotech innovators to integrate neoantigen approaches into broader immuno-oncology portfolios. The result is a robust ecosystem that fosters iterative improvements in efficacy, safety, and patient accessibility.
These paradigm shifts have prompted realignment of R&D priorities, with stakeholders increasingly focusing on combinatorial regimens that pair neoantigen therapies with checkpoint inhibitors or adoptive cell transfers. This integrative strategy aims to amplify antitumor immunity while mitigating mechanisms of immune evasion. In sum, the confluence of technological prowess, regulatory support, and strategic collaboration is redefining the trajectory of neoantigen targeted therapies.
Analyzing the Compound Effects of United States Tariffs in 2025 on Global Supply Chains and Access to Critical Components for Neoantigen Therapy Development
The introduction of new United States tariffs in 2025 has exerted a compounded effect on the global supply chains that underpin neoantigen therapy development. Many critical reagents, such as proprietary sequencing kits, custom oligonucleotides, and specialized cell culture media, originate from tariff-impacted jurisdictions. Consequently, manufacturers have encountered elevated procurement costs, which in turn influence overall production economics and downstream pricing models.
In response, several stakeholders have diversified sourcing strategies by establishing alternative supply nodes in lower-tariff regions or by vertically integrating key manufacturing steps. This reconfiguration of the supply chain has mitigated some cost pressures but has also necessitated additional capital investment in facility upgrades and quality control processes. At the same time, collaborative agreements between suppliers and developers have been renegotiated to share risk and reduce lead times for component delivery.
Moreover, the tariff environment has accelerated innovation in reagent design, prompting suppliers to develop in-house alternatives and generic substitutes that circumvent tariff-sensitive inputs. While these adaptations involve rigorous validation to ensure equivalence, they ultimately contribute to greater supply chain resilience. As a result, the industry is better positioned to maintain consistent production schedules and uphold stringent quality standards despite evolving trade policies.
Dissecting Multifaceted Segmentation Dynamics to Illuminate How Therapy Modalities Demographics Administration Routes and End Users Shape the Neoantigen Market
The neoantigen therapy market encompasses a sophisticated array of modalities, beginning with adoptive cell therapies such as CAR-T, TCR, and tumor-infiltrating lymphocytes that are engineered to recognize and eradicate tumor cells bearing unique mutation-derived antigens. Alongside these cell-based approaches, personalized neoantigen vaccines-ranging from dendritic cell constructs to nucleic acid vaccines and synthetic long peptides-leverage distinct mechanisms to prime the immune system against malignancy.
Treatment paradigms diverge further into monotherapy protocols, which isolate neoantigen strategies as standalone agents, and combination regimens that integrate checkpoint inhibitors or targeted biologics to potentiate immune activation. The selection of administration routes, whether oral formulations or parenteral delivery via intramuscular, intravenous, or subcutaneous injections, influences pharmacokinetic profiles and patient convenience. Age demographics, spanning adult, geriatric, and pediatric populations, necessitate tailored safety assessments and dosing strategies to address developmental and physiological differences.
Target disease indications, from bone and colorectal cancers to gynecological, non-small cell lung, and renal carcinomas, reflect the broad applicability of neoantigen therapeutics. End users including academic and government research institutes, hospitals and clinics, and specialty treatment centers shape adoption patterns based on infrastructure maturity and reimbursement frameworks. Each segmentation layer contributes unique insights into development priorities and market dynamics, guiding stakeholders toward optimized clinical strategies and resource allocation.
Mapping Regional Divergence in Neoantigen Targeted Therapeutics Adoption by Examining Market Drivers and Challenges across the Americas EMEA and Asia-Pacific Territories
Regional landscapes exhibit pronounced divergence in the uptake and maturation of neoantigen targeted therapies. In the Americas, robust investment ecosystems and well-established clinical trial networks drive rapid initiation of first-in-human studies and facilitate early adoption of personalized immunotherapies. Regulatory agencies in this region have demonstrated a willingness to grant breakthrough designations and provide scientific guidance that accelerates development timelines.
Across Europe, the Middle East, and Africa, varied regulatory frameworks and reimbursement mechanisms create both opportunities and challenges. Several countries have established innovation corridors to pilot advanced therapies under controlled access programs, while others navigate complex pricing negotiations and limited manufacturing capacity. Collaborative consortia are emerging to harmonize standards and share best practices for neoantigen identification and clinical validation.
In the Asia-Pacific region, expansive population bases and government-led biotechnology initiatives have spurred significant growth in research infrastructure. Nations within this territory are investing in regional manufacturing hubs and forging public-private partnerships to expedite local production of neoantigen kits and cell therapy platforms. Collectively, these strategic efforts are fostering a dynamic environment that supports both clinical innovation and commercial scalability.
Profiling Leading Innovators and Strategic Collaborators Driving the Evolution of Neoantigen Therapies with Their Unique Technological Advancements and Commercial Alliances
Leading innovators have emerged at the intersection of genomics, immunology, and biomanufacturing, advancing proprietary platforms for neoantigen discovery and validation. Several biotech enterprises have established integrated pipelines that span in silico epitope prediction, synthetic vaccine formulation, and GMP-compliant production of personalized therapies. Strategic alliances between cell therapy specialists and major pharmaceutical firms have further enhanced distribution capabilities and global reach.
Partnerships with academic research centers underpin collaborative efforts to refine antigen selection algorithms and to explore novel vaccine adjuvants. These alliances facilitate access to patient cohorts for biomarker discovery and early-phase trials. Additionally, contract development and manufacturing organizations have expanded their service offerings to support personalized immunotherapies, delivering end-to-end solutions from vector design to cryopreserved cell delivery.
Competitive differentiation is increasingly tied to the strength of intellectual property portfolios, the breadth of clinical pipelines, and successful demonstration of durable responses in late-stage trials. Companies that can seamlessly integrate cutting-edge bioinformatics, rapid manufacturing workflows, and strategic payer engagement are poised to capture leadership positions in this rapidly evolving sector.
Generating Strategic Imperatives and Operational Directives to Enable Industry Leaders to Capitalize on Neoantigen Therapy Innovations and Navigate Complex Regulatory Landscapes
Industry leaders should prioritize investment in scalable manufacturing platforms that can accommodate personalized production without compromising quality or regulatory compliance. Establishing flexible facilities equipped for both cell therapy expansion and vaccine assembly will enable rapid adaptation to emerging modalities. Concurrently, integrating advanced bioinformatics and machine learning tools will refine neoantigen prediction accuracy and reduce development cycles.
Engagement with regulatory authorities through early scientific advice and adaptive trial designs will de-risk clinical pathways and foster mutual understanding of novel endpoints. Forming cross-sector partnerships, including alliances with contract development and manufacturing organizations, will optimize resource utilization and expand geographic reach. Moreover, forging collaborations with payers and health technology assessment bodies can streamline reimbursement strategies and support value-based pricing models.
Finally, cultivating a robust ecosystem for data sharing-encompassing clinical outcomes, biomarker insights, and manufacturing performance-will accelerate collective learning and drive continuous improvement. By embracing these strategic imperatives, industry leaders can strengthen their competitive advantage and ensure sustainable growth in the neoantigen therapy arena.
Detailing the Comprehensive Research Framework Underpinning the Analysis Including Data Collection Techniques Expert Inputs and Analytical Models to Ensure Rigor
This research employs a holistic methodology combining primary and secondary data sources to ensure accuracy and comprehensiveness. Primary research involved in-depth interviews with key opinion leaders, industry executives, manufacturing specialists, and regulatory consultants to capture nuanced perspectives on technological trends and market dynamics. Secondary research encompassed an exhaustive review of peer-reviewed publications, clinical trial registries, patent filings, and regulatory filings to corroborate insights.
Data triangulation techniques were applied to validate findings across multiple sources and to identify areas of convergence and divergence. Quantitative data was supplemented with qualitative assessments to contextualize emerging themes. Analytical models, including trend analyses and scenario planning frameworks, were utilized to interpret the impact of external factors such as trade policies and demographic shifts.
A peer review process with external subject matter experts was conducted to ensure methodological rigor and to mitigate potential biases. All research activities adhered to ethical guidelines governing data privacy and intellectual property. The resulting insights reflect a balanced, evidence-based perspective on the evolving landscape of neoantigen targeted therapies.
Summarizing Pivotal Insights from the Neoantigen Therapeutics Landscape to Reinforce Strategic Priorities and Encourage Informed Decision Making in Precision Oncology
Neoantigen targeted therapies represent a transformative frontier in precision oncology, offering the promise of highly specific, patient-tailored immune interventions. Technological advances in genomic profiling, bioinformatics, and manufacturing have catalyzed rapid progress from discovery to clinical application. At the same time, evolving regulatory frameworks and strategic partnerships have created a fertile environment for innovation and commercialization.
However, challenges remain in the areas of supply chain resilience, reimbursement pathways, and scalable manufacturing. Tariff fluctuations, regional disparities in regulatory and infrastructure capacity, and the complexity of personalized production underscore the need for adaptive strategies. By understanding segmentation nuances across therapy modalities, demographic cohorts, administration routes, and therapeutic indications, stakeholders can better align research priorities with market opportunities.
Moving forward, sustained collaboration among industry, academia, regulators, and payers will be essential to fully realize the clinical and commercial potential of neoantigen therapies. As the field continues to mature, organizations that invest in cutting-edge technologies, strategic alliances, and data-driven decision making will be best positioned to lead the charge in this next era of cancer treatment.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
192 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising demand for personalized immunotherapies driving neoantigen innovation
- 5.2. Development of non-viral vector platforms for in vivo delivery of neoantigen-encoding mRNA therapies
- 5.3. Emergence of combination regimens pairing neoantigen vaccines with immune checkpoint blockade therapies
- 5.4. Advances in lipid nanoparticle delivery systems for mRNA-based neoantigen vaccines in oncology
- 5.5. Clinical translation of personalized neoantigen-specific T cell receptor therapies in advanced melanoma patients
- 5.6. Technological advances fueling growth in neoantigen-targeted therapy market
- 5.7. Advances in multi-epitope neoantigen delivery systems enhancing immune responses against solid tumors
- 5.8. Regulatory framework evolution guiding clinical development of individualized neoantigen immunotherapies
- 5.9. AI and genomics transforming neoantigen discovery and development
- 5.10. Implementation of digital twin simulations to predict patient-specific neoantigen immune engagement in silico
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Neoantigen Targeted Therapies Market, by Therapy Modality
- 8.1. Adoptive Cell Therapy
- 8.1.1. CAR-T Cell Therapy
- 8.1.2. T Cell Receptor (TCR) Therapy
- 8.1.3. Tumor‑infiltrating lymphocytes (TIL)
- 8.2. Personalized Neoantigen Vaccines
- 8.2.1. Dendritic Cell (DC) Vaccines
- 8.2.2. DNA/ RNA‑based Vaccines
- 8.2.3. Peptide (SLP) Vaccines
- 9. Neoantigen Targeted Therapies Market, by Treatment Approach
- 9.1. Combination Therapy
- 9.2. Monotherapy
- 10. Neoantigen Targeted Therapies Market, by Route of Administration
- 10.1. Oral
- 10.2. Parenteral
- 10.2.1. Intramuscular
- 10.2.2. Intravenous
- 10.2.3. Subcutaneous
- 11. Neoantigen Targeted Therapies Market, by Age Group
- 11.1. Adult
- 11.2. Geriatric
- 11.3. Pediatric
- 12. Neoantigen Targeted Therapies Market, by Target Disease Indication
- 12.1. Bone Cancer
- 12.2. Colorectal Cancer
- 12.3. Gynecological Cancer
- 12.4. Non-Small Cell Lung Cancer
- 12.5. Renal Cell Carcinoma
- 13. Neoantigen Targeted Therapies Market, by End-User
- 13.1. Academic & Government Research Institutes
- 13.2. Hospitals & Clinics
- 13.3. Specialty Clinics
- 14. Neoantigen Targeted Therapies Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Neoantigen Targeted Therapies Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Neoantigen Targeted Therapies Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. Achilles Therapeutics Limited
- 17.3.2. Agenus Inc.
- 17.3.3. AstraZeneca plc
- 17.3.4. BioNTech SE
- 17.3.5. Bristol‑Myers Squibb Company
- 17.3.6. CureVac N.V.
- 17.3.7. Eli Lilly and Company
- 17.3.8. EpiVax, Inc.
- 17.3.9. F. Hoffmann-La Roche AG
- 17.3.10. Genentech, Inc.
- 17.3.11. Genocea Biosciences, Inc.
- 17.3.12. Gilead Sciences, Inc.
- 17.3.13. GlaxoSmithKline plc
- 17.3.14. Gritstone bio, Inc.
- 17.3.15. Immatics N.V.
- 17.3.16. Immunomic Therapeutics, Inc.
- 17.3.17. IOVANCE Biotherapeutics, Inc.
- 17.3.18. Medigene AG
- 17.3.19. Merck & Co., Inc.
- 17.3.20. Moderna, Inc.
- 17.3.21. Neon Therapeutics, Inc.
- 17.3.22. Nykode Therapeutics
- 17.3.23. Pfizer Inc.
- 17.3.24. Precision Biologics
- 17.3.25. Valo Therapeutics Ltd
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
